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Abstract
Background: Heterogeneity is increasingly recognized in clinical
presentation of neuropathic pain (NP), but less often recognized in animal
models. Neurochemical dysregulation in rodent dorsal root ganglia (DRG)
is associated with peripheral nerve trauma, but poorly studied in
non-traumatic NP conditions.
Methods: This study aimed to investigate the temporal expressions of
activating transcription factor-3 (ATF-3), growth-associated protein-43
(GAP-43), neuropeptide Y (NPY) and galanin in traumatic and
non-traumatic rat models of neuropathies associated with NP. Expressions
of these markers were examined in the DRG at different time points
following tibial nerve transection (TNT) injury and antiretroviral drug
stavudine (d4T) administration using immunohistochemistry. The
development of sensory gain following these insults was assessed by
measuring limb withdrawal to a punctate mechanical stimulus.
Results: Both TNT-injured and d4T-treated rats developed hindpaw
mechanical hypersensitivity. Robust expressions of ATF-3, GAP-43, NPY
and galanin in both small- and large-sized L5 DRG neurons were observed
in the DRG from TNT-injured rats. In contrast, d4T-treated rats did not
exhibit any significant neurochemical changes in the DRG.
Conclusions: Taken together, the results suggest that ATF-3, GAP-43,
NPY and galanin are likely indicators of nerve trauma-associated processes
and not generic markers for NP. These experiments also demonstrate
distinct expression patterns of neurochemical markers in the DRG and
emphasize the mechanistic difference between nerve trauma and
antiretroviral drug-associated NP.
1. Introduction
Rodent models of nerve trauma are conventionally
used to elucidate neuropathic pain mechanisms and to
develop novel drugs. Although physical trauma to
peripheral nerves is one insult that may elicit neuro-
pathic pain in humans, the most widespread causes
arise from various aetiologies (Jensen, 2001), and
animal models are evolving to reflect that fact (Rice,
2010). Heterogeneity of presentations and mecha-
nisms of neuropathic pain has been increasingly
appreciated in the clinical domain (Baron et al., 2012),
but less so preclinically.
About 40% of patients whose HIV infection is oth-
erwise well controlled by antiretroviral therapies
(ART) suffer intractable neuropathic pain, and one of
the major factors underlying such a complication is a
neurotoxicity induced by certain ART drugs (Cherry
et al., 2012). Although toxic ART drugs are being
phased out, it will take considerable time to eliminate
the use of the cost-effective ART stavudine (d4T) in
many resource-limited settings. Thus, understanding
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the pathophysiology of ART-associated neuropathies is
a vital part of drug development. We, and others, have
shown that toxic ART-treated rats develop bilateral
hindpaw mechanical hypersensitivity and exhibit
complex pain-related behaviours (Joseph et al., 2004;
Huang et al., 2013) similar to those observed in nerve
trauma models (Hasnie et al., 2007). Moreover, these
animals had reduced intradermal nerve fibre density,
thus providing evidence of nerve damage (Wallace
et al., 2007; Huang et al., 2013).
Recently, differences in the dorsal root ganglion
(DRG) gene expression and spinal microgliosis have
been revealed between rodent models of peripheral
nerve trauma and chemotherapy- or ART-induced
peripheral neuropathy (Maratou et al., 2009; Zheng
et al., 2011a; Blackbeard et al., 2012).
Following nerve trauma, a number of neurochemi-
cal changes that have been linked to neuropathic pain
mechanisms (Hulse et al., 2012) occur within DRG
neurons, including the neuronal injury marker acti-
vating transcription factor-3 (ATF-3) (Tsujino et al.,
2000), neuropeptide Y (NPY) (Ma and Bisby, 1998),
galanin (Hokfelt et al., 1987) and growth-associated
protein-43 (GAP-43) (Sommervaille et al., 1991).
However, these studies are difficult to compare due to
different methodologies, species and strains used and
also because of variability of nerve injuries. Moreover,
these markers were mostly examined at specific single
time points post nerve trauma; thus, the temporal
expression profiles encompassing both the acute and
chronic stages of nerve injury as well as phenotypic
cell effects are not comprehensively documented.
Importantly, these markers have not been fully inves-
tigated in non-traumatic neuropathic pain models.
Only recently, we showed DRG expression of ATF-3
and NPY at 7 and 21 days following d4T treatment
(Huang et al., 2013).
In this study, we hypothesized that the temporal
expressions of neurochemical markers ATF-3, NPY,
galanin and GAP-43 in the d4T model are different to
those observed following tibial nerve transection
(TNT) injury in rats. The rationale for choosing ATF-3,
GAP-43, NPY and galanin is described in the Support-
ing Information Appendix S1.
2. Methods
2.1 Ethical statement
All experiments conformed to the UK Animal (Scientific
Procedures) Act 1986 and were conducted under the author-
ity of Home Office Project License PPL70/7162. We followed
International Association for the Study of Pain guidelines for
animal use and care and ARRIVE guidelines for data report-
ing (Zimmermann, 1983; Kilkenny et al., 2011).
2.2 Animal maintenance
Adult male Wistar rats (250–300 g; Charles River, Margate,
Kent, UK) were housed in temperature-controlled individu-
ally ventilated cages (21 °C, 1500 cm2 floor area, four per
cage), maintained on a 12:12 h light–dark cycle and provided
with normal rat chow food (Special Diet Services, Essex, UK)
and tap water ad libitum. Corncob soft bedding was used
(Lillico Biotechnology, Hookwood, Surrey, UK). Animals
were allowed to acclimatize in their housing environment
for at least 48 h following arrival, and all behavioural experi-
ments were performed during the light circle (7 a.m.–7
p.m.).
2.3 Study design
All treatments were assigned per cage and animals were
grouped based on survival times following hindpaw
mechanical sensory testing. TNT/sham-operated animals
(n = 36) were divided into the following groups: TNT day 1
(n = 3), sham day 1 (n = 4); TNT day 7 (n = 3), sham day 7
(n = 3); TNT day 14 (n = 3), sham day 14 (n = 4); TNT day
28 (n = 4), sham day 28 (n = 4); TNT day 43 (n = 4), sham
day 43 (n = 4). Animals treated with d4T/saline were divided
into the following groups: d4T day 7 (n = 4), saline day 7
(n = 4; d4T day 21 (n = 4), saline day 21 (n = 4); d4T day 43
(n = 4), saline day 43 (n = 4). Naïve animals (n = 4) did not
undergo any sensory testing assessment and were only used
as histological controls. Necessary steps, e.g., major domains
of good laboratory practice (Macleod et al., 2009), were
taken to minimize the impact of experimental bias (Support-
ing Information Table S1) on both hindpaw mechanical
sensory testing and immunohistochemical analysis.
2.4 Hindpaw withdrawal thresholds
Paw withdrawal thresholds (PWTs) to punctate mechanical
stimuli was measured using an electronic von Frey device
What’s already known about this topic?
• We know that there are differences in gene
expression and microgliosis in the dorsal root
ganglia between traumatic and non-traumatic
rodent models of neuropathic pain.
What does this study add?
• This study further elucidates the distinct differ-
ences in the neurochemical responses to nerve
damage in the dorsal root ganglia in the two
different models, highlighting the heterogeneity
of mechanisms underlying neuropathic pain
from different aetiologies.
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(Somedic, Horby, Sweden). Animals were placed into a
Plexiglas clear box (23 × 18 × 14 cm, Linton Instrument,
Norfolk, UK) with a 0.8 cm in diameter mesh floor, and
allowed to acclimatize (approximately 10–15 min). The cali-
brated force transducer (0.5 mm2 diameter tip) was applied
at a rate of 8–15 g/s to the mid-plantar surface of each
hindpaw until an active limb withdrawal response was
observed. A mean PWT was then calculated from a set of five
applications.
2.5 Immunohistochemistry
Naïve rats were immediately sacrificed and nerve-damaged
rats were sacrificed shortly after recording of hindpaw
mechanical responses with an intraperitoneal injection of
pentobarbital (300 mg/kg; Animal Care Ltd., York, UK) and
transcardially perfused with 200 mL of heparinized 0.9%
saline followed by 300 mL of 4% paraformaldehyde solution
(pH 7.4) in 0.1 M phosphate buffer. The L5 DRGs were
harvested and post-fixed in 4% paraformaldehyde for 2–4 h
and transferred to a 30% sucrose solution in 0.01 M
phosphate-buffered saline (PBS) for 72 h. DRGs were then
embedded in OCT mounting medium (VWR, Lutterworth,
UK). Serial cryostat sections (10 μm) were thaw mounted on
Superfrost® slides (VWR) allocated for individual animals.
Sectionswere rinsedwith PBS (3 × 10 min) before incubation
with PBS Triton (0.01 M PBS, 0.2% Triton and 0.1% sodium
azide) containing 10% normal goat serum for 1 h at room
temperature. Immunohistochemical reactions were con-
ducted overnight using the following primary antibodies
diluted in PBS Triton: rabbit anti-ATF-3 (1:200; Santa Cruz
Biotechnology, Dallas, TX, USA); rabbit anti-galanin (1:4000;
Peninsula Laboratories, San Carlos, CA, USA); rabbit anti-
NPY (1:1000; Peninsula Laboratories); rabbit anti-GAP-43
(1:1000; Chemicon, Watford, UK). For the identification of
cellular phenotype, sections were double labelledwithmouse
anti-peripherin (1:100; Santa Cruz Biotechnology or 1:1000;
Abcam, Cambridge, UK) or mouse anti-neurofilament 200
(1:1000; Sigma, Dorset, UK). Following incubation of primary
antisera, slides were rinsed (3 × 10 min) with PBS and incu-
bated using the following secondary bodies in PBS Triton: goat
anti-mouse Alexa flour 568 (1:400; Invitrogen, Paisley, UK)
and goat anti-rabbit Alexa flour 488 (1:400; Invitrogen). Then
sections were washed in PBS and incubated with 2 μg/mL of
Hoechst 33342 (Sigma) diluted in distilled water for 2 min,
and coverslipped with PBS/glycerol (1:8). Negative controls
were carried out for each primary antibody used by omission
of primary antisera.
2.6 Image analysis and quantiﬁcation
Fluorescent images were visualized using a fluorescence
microscope (Leica, Linford Wood, Bucks, UK), equipped
with appropriate filter blocks and captured at consistent
exposure times using a charge-coupled device camera
(Model 3CCD c5810; Hamamatsu, Hamamatsu City, Japan).
Images were analysed using QWin v.3.0 software (Leica). All
images were taken at ×10 objective magnification. For each
animal a total of three serial sections (at least 150 μm apart)
representing the beginning, middle and end sections of the
DRG were used to take images for analysis. These three
sections were comparable between animals. Monochromatic
grey scale images were loaded onto QWin, and a binary
overlay was created based on the pixel intensity immunore-
active cells. The threshold for immunoreactivity was deter-
mined for each section when there was a clear demarcation
point between background and immunoreactivity. Back-
ground was determined by selecting an area of the DRG
where immunolabelling was not present, and this value was
subtracted from the threshold level for immunoreactivity. A
binary overlay was constructed based on the intensity and
number of pixels of each image, to identify immunoreactive
cells. The total number of peripherin/NF-200 immunoreac-
tive neurons expressing immunoreactivity for ATF-3, GAP-
43, NPY and galanin was determined and expressed as a
percentage of the total number of peripherin/NF-200 immu-
noreactive neurons for each animal. A mean percentage was
then determined for each group. Parallel colour images were
taken with nuclear marker Hoechst 33342 and immunore-
active cells cross-checked so that only cells with a demon-
strable nucleus were analysed.
2.7 Statistical analysis
Sigmastat version 3.5 (Systat Software, Erkrath, Germany)
was used to determine statistically significant differences
throughout the study. p < 0.05 was considered statistically
significant. To compare mean PWT at baseline and at each
subsequent time point, a Student’s paired t-test was per-
formed. To compare the temporal profiles of neurochemical
markers a one-way analysis of variance (ANOVA) with
Holm–Sidak post hoc was performed. A two-way ANOVA
followed by Holm–Sidak post hoc test was used to analyse
intervention effects (nerve-damaged rats vs. control) and cell
size effects (NF-200 vs. peripherin) at each time point. All
data are represented as mean ± standard error of the mean.
3. Results
3.1 Exclusions
For the TNT experiments, two rats were excluded (at
day 1 and day 14 post-injury) due to incorrect nerve
injury that was confirmed at post-mortem. No d4T rats
were excluded.
3.2 Temporal development of hindpaw
mechanical hypersensitivity following TNT
injury or d4T treatment
The temporal effects of TNT injury on the percentage
decreases in ipsilateral PWTs from baseline were com-
parable with that observed in d4T-treated rats (Fig. 1).
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The time course of TNT and d4T-associated mechanical
hypersensitivity can be observed in Supporting Infor-
mation Figs. S1 and S2. Percentage changes in d4T-
treated rats were averaged from both hindpaws due to
similar degrees of bilateralmechanical hypersensitivity.
In the acute stages of nerve trauma, day 1 post-TNT
injury, rats exhibited a 22 ± 11.4% decrease in ipsilat-
eral PWTs. The decrease in PWTs increased further at
day 7 post-TNT injury to 45.1 ± 6.1%, while d4T-
treated rats at 7 days post the first injection demon-
strated a 31.0 ± 1.7% reduction in PWTs. At day 14
post-TNT injury, rats exhibited a 37.3 ± 3.4% decrease
in ipsilateral PWTs. At day 28 post-TNT injury, the
decrease in ipsilateral PWTs peaked at 61.1 ± 2.9%
while at 22 days post the first d4T injection, the
decrease in PWTs peaked at 47.5 ± 1.8%. At the longest
experimental time point of 43 days, TNT-injured rats
demonstrated a decrease in ipsilateral PWTs of
37.6 ± 5.8% while in d4T-treated rats, PWTs decreased
by 17 ± 1.8%. Mechanical hypersensitivity was not
observed in sham animals throughout the study.
3.3 ATF-3 expression
Consistent with the literature (Tsujino et al., 2000),
ATF-3 immunoreactivity was not evident in DRGs har-
vested from naïve rats (Supporting Information
Table S2). TNT injury was associated with significant
ATF-3 up-regulation in both NF-200 and peripherin
cell populations when compared with sham rats
[p < 0.05; Fig. 2A(i); Fig. 3] except at 1 day post-injury
in peripherin-immunoreactive cells, and 43 days post-
injury in NF-200-immunoreactive cells. ATF-3 immu-
noreactivity was nuclear (Fig. 3). A significant
temporal profile effect was observed in NF-200-
immunoreactive cells in TNT-injured rats (p < 0.05),
which was particularly evident at 1 day after nerve
injury, but not in peripherin-immunoreactive cells.
Following d4T treatment, ATF-3 immunoreactivity
was observed in very few NF-200 and peripherin-
immunoreactive cells. Mean percentage ATF-3 immu-
noreactivity in NF-200 and peripherin cells was <1%
across all time points. No significant differences were
observed between percentage ATF-3 immunoreactiv-
ity in NF-200 and peripherin-immunoreactive cells at
various time points examined and no temporal profile
effects were observed [Fig. 2A(ii); Fig. 3].
3.4 GAP-43 expression
GAP-43 immunoreactivity in naïve DRGs was only
observed in few NF-200-immunoreactive cells (<2%;
Supporting Information Table S2) and not in the
peripherin-immunoreactive population. GAP-43
immunoreactivity was cytoplasmic in nature and was
observed in both NF-200 and peripherin DRG cell
populations, and additionally observed in axons
(Fig. 4). TNT injury was associated with significant
GAP-43 up-regulation in both NF-200 and peripherin-
immunoreactive cells at different time points post-
injury compared with sham-operated rats [p < 0.05;
Fig. 2B(i); Fig. 4]. Significant temporal profile effects
were evident in the NF-200 (p < 0.05) but not the
peripherin-characterized cell populations.
Following d4T treatment, GAP-43 immunoreactiv-
ity was observed in few NF-200 and peripherin-
immunoreactive cells. Mean percentage GAP-43
immunoreactivity in NF-200 and peripherin-
characterized cells was <5% across all time points and
was not significantly different to that observed in
respective saline-treated rats. No significant differ-
ences in GAP-43 immunoreactivity were observed
between NF-200 and peripherin-immunoreactive cell
populations at various time points examined. A sig-
nificant temporal profile of GAP-43 immunoreactivity
was observed in the peripherin-immunoreactive cells
of d4T-treated rats and in the NF-200-immunoreactive
cells of saline-treated rats [Fig. 2B(ii); Fig. 4].
3.5 NPY expression
NPY immunoreactivity in naïve DRGs was only
observed in few NF-200-immunoreactive cells
(<0.3%; Supporting Information Table S2) and not in
peripherin-immunoreactive cells. NPY immunoreac-
tivity was largely cytoplasmic, although some
Figure 1 Mean percentage change in paw withdrawal threshold (PWT)
from baseline at various time points post tibial nerve transection (TNT)
injury and d4T treatment in response to punctate mechanical stimulation.
PWT data regarding both hindpaws of d4T rats were pooled since both
sets of data were identical.
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Figure 2 Mean percentage of total NF-200
and peripherin cells immunoreactive for (A)
activating transcription factor-3 (ATF-3), (B)
growth-associated protein-43 (GAP-43), (C)
neuropeptide Y (NPY) and (D) galanin in (i) ipsi-
lateral L5 dorsal root ganglia (DRGs) of tibial
nerve transection (TNT) and sham animals; and
(ii) the left L5 DRGs of d4T-injected animals.
Data are presented as mean ± standard error
of the mean. Statistical test at each time point
was conducted using a two-way analysis of
variance followed by Holm–Sidak post hoc
analysis: *p < 0.05 versus respective sham;
+p < 0.05 versus peripherin-immunoreactive
neurons; #p < 0.05 versus NF-200-
immunoreactive neurons. §p < 0.05 TNT
(peripherin) versus sham (peripherin).
Figure 3 Representative images of activating transcription factor-3 (ATF-3) immunoreactivity. The left three columns are for ATF-3 expression in ipsilateral
L5 dorsal root ganglia (DRGs) at 1 and 28 days post tibial nerve transection (TNT) injury and at 28 days post sham surgery. The right two columns are for
ATF-3 expression in the left L5 DRGs of d4T/saline-treated rats at 7 days post ﬁrst injection. Sections were co-labelled with peripherin (top row) and NF-200
(bottom row) to identify ATF-3 immunoreactivity in distinct populations of DRG neurons. Images were captured at ×20 objective magniﬁcation. Arrows
indicate co-localization of immunolabelling. Scale bar = 50 μm.
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immunoreactivity was observed in axons (Supporting
Information Fig. S3). TNT injury was associated with
robust NPY immunoreactivity, particularly in the
NF-200-immunoreactive cells [Fig. 2C(i); Supporting
Information Fig. S3]. Significant temporal profiles
were observed in both peripherin and NF-200-
immunoreactive cells [p < 0.05; Fig. 2C(i); Supporting
Information Fig. S3].
Following the administration of d4T to rats, NPY
immunoreactivity was observed in few NF-200 and
peripherin-immunoreactive cells. Mean percentage
NPY immunoreactivity in NF-200 and peripherin-
immunoreactive cells was <0.5% across all time
points. No significant differences were observed
between percentage NPY immunoreactivity in NF-200
and peripherin-immunoreactive cells at various time
points examined and no temporal profile effects were
observed [p > 0.05; Fig. 4C(ii); Supporting Informa-
tion Fig. S3].
3.6 Galanin expression
Galanin immunohistochemistry in naïve DRGs was
only observed in few peripherin-immunoreactive cells
(<0.6%, Supporting Information Table S2) and not in
NF-200-immunoreactive cells. Galanin exhibited a
diffuse granule-like cytoplasmic immunoreactivity in
both NF-200 and peripherin-immunoreactive cells
(Supporting Information Fig. S4). TNT injury was
associated with significant galanin immunoreactivity
in both NF-200 and peripherin-immunoreactive cells
when compared with respective sham rats at particu-
lar time points post-injury, and both cell populations
demonstrated dynamic and similar significant tempo-
ral profiles [p < 0.05; Fig. 2D(i); Supporting Informa-
tion Fig. S4].
Following the administration of d4T to rats, galanin
immunoreactivity was observed in few NF-200 and
peripherin-immunoreactive cells. Mean percentage
galanin immunoreactivity in NF-200 and peripherin-
characterized cells was <2% across all time points. No
significant differences were observed between per-
centage galanin immunoreactivity in NF-200 and
peripherin-immunoreactive cells at various time
points examined and no temporal profile effects were
observed [p > 0.05; Fig. 2D(ii); Supporting Informa-
tion Fig. S4].
4. Discussion
Here, we revealed distinct differences in DRG neuro-
chemical response following traumatic TNT injury and
systemic exposure to the antiretroviral drug d4T in
adult rats. These models have fundamental differences
regarding the nature of the nerve damage, yet are both
associated with neuropathic pain clinically and with
features suggestive of neuropathic pain in animals
(Andrews et al., 2012; Huang et al., 2013). Crucially, in
both animal models, similar degrees of hindpaw
mechanical hypersensitivity were documented. The
onset of mechanical hypersensitivity in TNT animals
was comparable with previous reports 2–3 weeks fol-
lowing injury lasting for at least 2 months (Andrews
et al., 2012). Similarly, in d4T-treated animals,
mechanical hypersensitivity was consistent with obser-
vations from animal studies using the neurotoxic anti-
retroviral drug zalcitabine (ddC) (Wallace et al., 2007).
Experimental peripheral nerve injury induces
several neurochemical changes in the DRGs that may
play a role in abnormal pain states. Our study is the
first to examine such changes following TNT injury
using immunohistochemical analysis and additionally
Figure 4 Representative images of growth-associated protein-43 (GAP-43) immunoreactivity. The left three columns are for GAP-43 expression in
ipsilateral L5 dorsal root ganglia (DRGs) at 1 and 14 days post tibial nerve transection (TNT) injury and at 14 days post sham surgery. The right two columns
are for GAP-43 expression in the left L5 DRGs of d4T/saline-treated rats at 7 days post ﬁrst injection. Sections were co-labelled with peripherin (top row)
and NF-200 (bottom row) to identify GAP-43 immunoreactivity in distinct populations of DRG neurons. Images were captured at ×20 objective magniﬁ-
cation. Arrows indicate co-localization of immunolabelling. Scale bar = 50 μm.
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compared with the d4T-associated neuropathy model.
Following TNT injury, ATF-3 was significantly
up-regulated in the ipsilateral L5 DRG in both periph-
erin and NF-200 DRG neurons at all time points com-
pared with sham controls. At day 1 post-TNT injury,
ATF-3 expression was significantly greater in large
diameter NF-200 expressing cells (71%) compared
with the smaller sized peripherin-expressing cells
(25%). This may be a reflection on the differing
degrees of injury sustained between small- and large-
sized neurons or different responses of these neuronal
types following TNT injury. In certain types of nerve
trauma such as chronic constriction injury, large
myelinated fibres incur greater levels of damage and
degeneration than unmyelinated fibres (Basbaum
et al., 1991), although such changes were observed at
10–14 days post-injury. The biological role of ATF-3 is
not entirely clear. Its up-regulation may be indicative
of other processes such as nerve regeneration (Seijffers
et al., 2007).
The increased ATF-3 immunoreactivity in the DRG
after nerve injury is also associated with dysregulated
neuropeptide expression, particularlyNPY and galanin.
From at least day 7 following TNT injury, NPY was
up-regulated primarily in NF-200-immunoreactive
cells (peak at day 14 post-injury ∼51%), but also in a
modest percentage of peripherin cells (1–6.5%). The
cell size effect and magnitude of immunoreactivity
correlates with previous studies (Ma and Bisby, 1997).
The exact role of NPY is unclear, but evidence has
implicated NPY in antinociception (Intondi et al.,
2008). The significant temporal increase in NPY immu-
noreactivity in small-sized peripherin-immunoreactive
cells seenheremay therefore represent a compensatory
mechanism to reduce excessive nociception related to
neuropathic pain processes.
Galanin exhibited a similar temporal expression
patterns between peripherin and NF-200-
immunoreactive DRG cells after TNT injury in this
study. Pharmacological studies have shown galanin to
be antinociceptive in naïve rats, although at low doses
(Wiesenfeld-Hallin et al., 1988). Galanin deletion
impairs the ability of peripheral nerves to regenerate
following sciatic nerve crush and loss-of-function
galanin mutations are associated with increased apop-
tosis and a loss of DRG neurons (Holmes et al., 2000),
therefore galanin may regulate nerve regeneration
and neuroprotective processes.
Nerve regeneration following nerve trauma has
been associated with increased GAP-43 immunoreac-
tivity in the DRGs (Sommervaille et al., 1991). TNT
injury initiated GAP-43 up-regulation, with similar
temporal profile expressions between peripherin and
NF-200 cells. A cell size effect was observed at day 7
post-injury, which corroborates with previous studies
demonstrating GAP-43 mRNA up-regulation in ini-
tially small DRG neurons before a subsequent increase
in large DRG neurons after nerve trauma (Wiese et al.,
1992). GAP-43 modulates the formation of new neu-
ronal connections and may be involved in the guid-
ance of growing axons endings (Benowitz and
Routtenberg, 1997). GAP-43 expression may also be
related to the interruption of axonal transport since its
inhibition can induce immunoreactivity identical to
nerve crush injury (Woolf et al., 1990).
Although there appears to be an associative trend,
our investigations revealed no correlations between
the percentage immunoreactivity of investigated neu-
rochemical markers and the degree of pain-related
mechanical hypersensitivity following TNT injury. This
result concurs with previously reported observations
regarding ATF-3 (Shortland et al., 2006) and GAP-43
(Jaken et al., 2011).
The neurochemical dysregulation observed follow-
ing TNT injury was not apparent in the DRGs har-
vested from d4T-treated rats, which is in agreement
with our previous findings also demonstrating a lack
of ATF-3, NPY and galanin immunoreactivity in the
DRGs of rats at 21 days after systemic treatment with
the ddC (Wallace et al., 2007). In contrast to the d4T
model, TNT-injured rats demonstrated an apparent
DRG neurochemical response that manifested in the
expression of ATF-3, NPY, galanin and GAP-43; all
findings consistent with literature reports. Our
results suggest these neurochemical markers are
likely indicators of nerve trauma-associated processes
and not specific generic biomarkers of neuropathic
pain mechanisms.
The differences in neurochemical marker expression
could reflect differences in other sensory modalities
such as cold or thermal. There is evidence supporting
thermal hypersensitivity in ddC-treated rats (Joseph
et al., 2004), while other studies regard thermal
hypersensitivity to not be a consequence of ddC
(Wallace et al., 2007) or d4T treatment (Renn et al.,
2011). This inconsistency makes this a less reliable
measurement of pain-related behaviour.
The lack of neurochemical marker expression in
d4T-treated rats could be linked to apoptotic DRG-
related neuronal death. The apoptotic marker-
activated caspase-3 is present in the DRGs of nerve
trauma-injured rats (Sekiguchi et al., 2009), at a time
when neurochemical markers such as that observed in
our study is also present. Therefore, it is unlikely apop-
tosis is the cause of the lack of neurochemical marker
expression in d4T-treated rats.
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Distinct responses to nerve damage between these
two models are also observed at gene level within the
DRGs (Maratou et al., 2009) and with regard to spinal
microglia infiltration, which is relatively modest in
d4T/ddC-treated rats, compared with that in rats with
nerve trauma (Zheng et al., 2011a; Blackbeard et al.,
2012; Huang et al., 2013).
Our results also indicate fundamental mechanistic
heterogeneity in the manifestation of neuropathic
pain between traumatic and non-traumatic nerve
damage. The pathological processes responsible for
d4T/ddC-associated neuropathy are likely linked to
mitochondrial dysfunction (Payne et al., 2011;
Huang et al., 2013), a feature perhaps less relevant in
nerve trauma. Such mitochondrial dysfunction is
supported via experimental evidence documenting
altered calcium homeostasis (Joseph et al., 2004)
and activation of pro-apoptotic caspase pathways
(Joseph and Levine, 2004). Oxidative stress may play
a role, and the removal of reactive oxygen species by
scavengers is reported to reverse mechanical hyper-
sensitivity in ddC-treated rats (Zheng et al., 2011b).
The lack of ATF-3 and NPY immunoreactivity in the
DRG of d4T-treated rats parallels our recent study,
which has additionally demonstrated normal CGRP
and IB4 expression following d4T administration
(Huang et al., 2013). These observations, in conjunc-
tion with studies demonstrating a clear neurotoxicity
involving retraction of nerve fibres from paw skin
(Wallace et al., 2007; Huang et al., 2013), is sugges-
tive of a mechanism not involving the DRGs, in con-
trast to nerve trauma models where many
neurochemical changes occur within the DRGs.
However, reports of increased immunoreactivity of
pronociceptive macrophage chemoattractant CCL2
(Wallace et al., 2007) and lymphocyte chemoattrac-
tant CXCL12 (Bhangoo et al., 2007) in the DRGs of
ddC-treated rats indicates involvement of an inflam-
matory mechanism and perhaps does not entirely
rule out pathological processes within the DRGs with
this type of injury, although we did not observe
increased infiltration of macrophages in the DRGs of
d4T-treated rats previously (Huang et al., 2013).
Proteomic analysis in the sural nerve of d4T-
treated rats has revealed the down-regulation of
microtubule-associated protein 1B that may be
involved in the ‘dying back’ pathology (Huang et al.,
2013). The spinal cord may also be involved, with
increases in dorsal horn BDNF expression (Renn
et al., 2011) and length-dependent reductions in
CGRP and IB4 expression in the superficial lamina of
the spinal dorsal horn in d4t-treated rats (Huang
et al., 2013).
5. Conclusion
This study has revealed that there are distinct differ-
ences in the neurochemical responses to nerve
damage in the DRGs in two different types of nerve
damage that are both associated with neuropathic
pain, highlighting the heterogeneity of the mecha-
nisms of neuropathic pain from different aetiologies.
Evidence from clinical studies have shown that neu-
ropathic pain patients can exhibit varying pain symp-
toms and sensory profiles revealed by quantitative
sensory testing, even those with similar aetiologies,
revealing the heterogeneity of neuropathic pain and
the likelihood of various pain mechanisms (Maier
et al., 2010; Baron et al., 2012). This proposes the
prospect that neuropathic pain research can be
approached in terms of its presumed mechanisms,
irrespective of aetiology, and if those mechanisms are
targeted specifically, it may allow an optimum treat-
ment regime that could lead to better neuropathic
pain management (Finnerup et al., 2010).
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Figure S1. Time course of TNT-associated mechanical
hypersensitivity. The PWT to punctate mechanical stimuli
was measured in different groups of animals examined at 1,
7, 14, 28 and 43 days following TNT and sham surgery.
Baseline PWTs were determined for all operated animals
prior to surgery. Data are presented as mean ± SEM.
**p < 0.01 and *p < 0.05 versus respective baseline levels
using a Student’s paired t-test.
Figure S2. Time course of d4T-associated mechanical
hypersensitivity. The PWT to punctate mechanical stimuli
were measured in left and right hind limbs at the various
time point post d4T/saline injections. Data are presented as
mean ± SEM. **p < 0.01 and *p < 0.05 versus respective
baseline levels using a Student’s paired t-test.
Figure S3. Representative images of NPY immunoreactiv-
ity. The left panel is for NPY expression in ipsilateral L5 DRGs
at 1 and 14 days post-TNT injury and at 14 days post-sham
surgery. The right panel is for NPY expression in the left L5
DRGs of d4T/saline-treated rats at 7 days post first injection,
and in the L5 DRGs of naïve animals. Sections were
co-labelled with peripherin and NF-200 to identify NPY
immunoreactivity in distinct populations of DRG neurons.
Images were captured at ×20 objective magnification.
Arrows indicate co-localization of immunolabelling. Scale
bar = 50 μm.
Figure S4. Representative images of galanin immunoreac-
tivity. The left panel is for galanin expression in ipsilateral L5
DRGs at 1 and 14 days post-TNT injury and at 14 days
post-sham surgery. The right panel is for galanin expression
in the left L5 DRGs of d4T/saline-treated rats at 7 days post
first injection, and in the L5 DRGs of naïve animals. Sections
were co-labelled with peripherin and NF-200 to identify
galanin immunoreactivity in distinct populations of DRG
neurons. Images were captured at ×20 objective magnifica-
tion. Arrows indicate co-localization of immunolabelling.
Scale bar = 50 μm.
Table S1. Major domains of good laboratory practice to
minimize the effects of experimental bias on both hindpaw
mechanical sensory testing and immunohistochemical
analysis.
Table S2. Mean percentage immunoreactivity and mean
cell area (μm2) of ATF-3, GAP-43, NPY and galanin in
NF-200 and peripherin-immunoreactive cells in naïve L5
DRGs. Data are presented as mean ± SEM. The numbers of
ATF-3, GAP-43, NPY and galanin immunoreactivity cells out
of the total number of peripherin/NF-200-immunoreactive
cells are indicated in brackets (n/a, not applicable as no data
was available).
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